The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland ...

Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial. The global randomized study demonstrat ...

Boston Scientific (NYSE: BSX) today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, ...

Surmodics (SRDX) announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil drug-coated ...

Ulf Teichgräber “Historically, paclitaxel-coated balloon angioplasty has been the mainstay therapy for PAD, particularly in the femoropopliteal vascular segment, and is based on the “leaving ...